# A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

> **NCT01111903** · PHASE1,PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 67 (actual)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01111903
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01111903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01111903, "A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01111903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*